Tiragolumab

Unassigned

New Medicines

Extensive-stage small cell lung cancer (SCLC) - first-line in combination with atezolizumab and chemotherapy

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Immunotherapy, interfers with with a protein called PD-L1 (Programmed Death-Ligand 1).
SCLC accounts for about 15% of cases of lung cancer. There were 46,403 new cases diagnosed in the UK in 2014. 53% were males and 47% were females. More than 35,000 people die from the condition [1].
Extensive-stage small cell lung cancer (SCLC) - first-line in combination with atezolizumab and chemotherapy
Intravenous infusion

Metastatic non-small cell lung cancer (NSCLC), that expresses PD-L1 - first-line in combination with atezolizumab

Information

Licence extension / variation
Roche
Roche

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Immunotherapy, interfers with with a protein called PD-L1 (Programmed Death-Ligand 1).
UK incidence of advanced NSCLC is 40 per 100,000.
Metastatic non-small cell lung cancer (NSCLC), that expresses PD-L1 - first-line in combination with atezolizumab
Intravenous infusion